Please try another search
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ:CRSP) on Friday, setting a price target of $171, which is approximately 43.70% above the present share price of $119.
Livshits expects Crispr Therapeutics AG to post earnings per share (EPS) of -$1.51 for the third quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in Crispr Therapeutics AG, with an average price target of $173.83.
The analysts price targets range from a high of $220 to a low of $132.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $539 thousand and a net profit of -$114.54 million. The company's market cap is $9.56 billion.
According to TipRanks.com, Chardan Capital analyst Geulah Livshits is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 78.0% and a 62.09% success rate.
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.